Imatinib can save 100000 US dollars in 5 years for patients with expired patent of anticancer drug Gleevec

Source: www.qiaobao.com.cn on March 18, 2016, scientists from Johns Hopkins University in the United States said that if the anticancer drug gleevac was replaced by imatinib, it could save 100000 dollars for patients in five years and more than 9 million dollars for insurance companies with 100 patients When imatinib was put on the market, its price was only one tenth of that of Gleevec, according to UPU Gleevec is a tyrosine kinase inhibitor that can be used in the treatment of chronic myeloid leukemia and can help patients who do not relapse within 5 years to survive During this period, in order to reduce side effects, patients have been circling between Gleevec, dasatinib and nilotinib These three drugs have similar survival rate for leukemia patients, but they are all relatively expensive They need to spend 60000 to 80000 US dollars per year for patients If the price is lowered in the future, it will bring good news for patients, doctors and insurance companies William Padula, assistant professor of health and strategy management at Johns Hopkins University, said that when the patent for the drug expires, the price of imatinib will be closer to the real value of the drug The latest study, published in the Journal of the National Cancer Institute, scientists built mathematical models to assess the five-year efficacy of imatinib Imatinib can help patients save $100000 in five years after replacing Gleevec If the annual cost of Gleevec is $60000, imatinib only needs $6000.